• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Philips wins FDA clearance for next-gen digital pathology system

Philips wins FDA clearance for next-gen digital pathology system

July 12, 2024 By Sean Whooley

Philips IntelliSite Pathology Solution 5.1
[Image courtesy of Philips]
Philips (NYSE: PHG) announced today that it received FDA clearance for its latest pathology solution, the IntelliSite Pathology Solution 5.1.

IntelliSite Pathology supports remote collaboration and teamwork, aiding diagnosis, boosting productivity, addressing staff shortages and cutting costs. The comprehensive, scalable system integrates hardware, software, storage, analysis and enterprise-wide connectivity. It provides pathologists with fully integrated, end-to-end workflows to deliver accurate diagnoses and improve patient outcomes.

Earlier this year, Philips struck a deal with Amazon Web Services (AWS) to advance digital pathology with IntelliSite. This itengration enables third-party, AI-driven diagnostic applications.

IntelliSite Pathology helps shorten the time needed to review, report and sign off on cases while also allowing pathologists to work remotely. Philips says that enabling remote collaboration and leveraging cloud-based AI, clinicians can deliver timely precision diagnoses. By securely lifting data out of the pathology lab, care teams can access it at every stage of the patient journey, too.

Philips’ open-platform approach to data also facilitates medical research and could enable the development of new diagnostic algorithms. The company says it could also help develop disease biomarkers and treatment options.

“Digital pathology is helping to revolutionize how we diagnose and potentially treat cancer. With the 510(k) approval we expand our ability to help pathology laboratories transform to fully digital workflows, saving time and easing the burden on pathologists and patients,” said Martijn Hartjes, clinical informatics business leader at Philips. “We are advancing the digital transformation in pathology and multi-disciplinary clinical collaboration between pathologists, radiologists, oncologists, and other healthcare professionals, empowering clinicians with the tools they need to deliver improved patient outcomes and care.”

Filed Under: 510(k), Artificial Intelligence (AI), Big Data, Diagnostics, Digital Health, Electronic Medical Records (EMR), Food & Drug Administration (FDA), Health Technology, Machine Learning (ML), Oncology, Regulatory/Compliance, Software / IT Tagged With: FDA, Philips, Royal Philips

More recent news

  • Carlsmed names chief product and AI officer as it claims CMS reimbursements
  • Integra LifeSciences says Cincinnati plant flooding will cost millions
  • Mendaera rolls out handheld needle robot paired with Butterfly ultrasound probe
  • Edwards earns FDA approval for first-of-its-kind size-adjustable pediatric heart valve
  • Leading medical device experts and MDO launch Medtech Innovation Board

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy